Latest Lead News

Imugene Limited has launched a $37.5 million equity raising through a Placement and Share Purchase Plan, offering new shares and options to fund its pivotal azer-cel clinical program. The raise includes attaching and piggyback options, subject to shareholder approval, aiming to bolster the company’s immuno-oncology pipeline.

Imugene Limited has launched a A$37.5 million capital raising to advance its promising off-the-shelf CAR T therapy, azer-cel, following encouraging Phase 1b data showing a 75% overall response rate in lymphoma patients.

Hawsons Iron Limited has successfully raised $1.91 million through an oversubscribed Share Purchase Plan and a targeted Placement, positioning the company to fast-track key project studies and environmental assessments.

Future Generation Global has reported a strong 20.8% investment portfolio return for the year ending June 2025, prompting an increase in its fully franked interim dividend to 4.0 cents per share. This marks the sixth consecutive year of dividend growth for the ASX-listed investment company.

ImpediMed has doubled its US unit sales in Q4 FY25, achieving a record total contract value and securing an additional $5 million tranche under its growth capital facility.

Lord Resources has successfully raised $1.39 million through a shortfall placement, setting the stage for imminent drilling at its high-grade Ilgarari Copper Project in Western Australia.

DigitalX Limited reports a $75.6 million treasury valuation driven by Bitcoin and digital assets, completing a $20.7 million capital raise to expand its Bitcoin-first strategy.

Close the Loop Limited announces a strategic leadership overhaul with new CEOs appointed for North America and Australia, alongside a streamlined operational focus on three core business units.

Critica Limited reports breakthrough metallurgical test results at its Jupiter Project, achieving a 95% mass reduction and upgrading rare earth grades, including heavy rare earth oxides. This positions Jupiter as a key player in Australia’s strategic rare earth supply chain.

Prescient Therapeutics has initiated its first US clinical site for the PTX-100 Phase 2a trial targeting Cutaneous T-Cell Lymphoma, marking a key milestone in expanding patient recruitment beyond Australia.

Dalaroo Metals has raised $1 million through a strategic placement supported by cornerstone investors including local partners in Cote d’Ivoire, while announcing the resignation of its CEO. The funds will accelerate exploration across multiple regions and support new project evaluations.

Many Peaks Limited has raised A$13.5 million through a private placement to fund its inaugural Mineral Resource Estimate and exploration at Ferke South, while also increasing director remuneration to reflect company growth.